Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 399

1.

Use of Lasers for Iron-Induced Accidental Tattoos: Experience at a Tertiary Referral Center.

Eggenschwiler CDC, Dummer R, Imhof L.

Dermatol Surg. 2019 Nov 6. doi: 10.1097/DSS.0000000000002262. [Epub ahead of print]

PMID:
31714385
2.

Efficacy and safety of Colchicine in inflammatory skin diseases: a retrospective, monocentric study in a large tertiary center.

Anzengruber F, Graf V, Hafner J, Meienberer N, Guenova E, Dummer R.

J Dermatolog Treat. 2019 Nov 7:1-25. doi: 10.1080/09546634.2019.1690621. [Epub ahead of print]

PMID:
31694429
3.

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy.

Dimitriou F, Mangana J, Dummer R.

Acta Derm Venereol. 2019 Oct 18. doi: 10.2340/00015555-3355. [Epub ahead of print] No abstract available.

4.

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Nathan P.

Eur J Cancer. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014. Epub 2019 Sep 30.

PMID:
31581055
5.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Michielin O, van Akkooi A, Ascierto P, Dummer R, Keilholz U; ESMO Guidelines Committee.

Ann Oncol. 2019 Sep 30. pii: mdz411. doi: 10.1093/annonc/mdz411. [Epub ahead of print] No abstract available.

PMID:
31566661
6.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD.

N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.

PMID:
31562797
7.

Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase 2 randomised, double-blind BOLT study.

Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, Combemale P, Dirix L, Kaatz M, Kudchadkar R, Loquai C, Plummer R, Schulze HJ, Stratigos AJ, Trefzer U, Squittieri N, Migden MR.

Br J Dermatol. 2019 Sep 23. doi: 10.1111/bjd.18552. [Epub ahead of print]

PMID:
31545507
8.

Dapsone in a Large Tertiary Center: Outdated Therapeutic Option or Timeless Agent?

Anzengruber F, Schenk J, Graf V, Nordmann TM, Guenova E, Dummer R.

Dermatology. 2019 Sep 11:1-8. doi: 10.1159/000502256. [Epub ahead of print]

PMID:
31509850
9.

Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma.

Freiberger SN, Morand GB, Turko P, Wager U, Dummer R, Hüllner M, Holzmann D, Rupp NJ, Levesque MP.

Cancers (Basel). 2019 Sep 7;11(9). pii: E1329. doi: 10.3390/cancers11091329.

10.

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.

Weide B, Eigentler T, Catania C, Ascierto PA, Cascinu S, Becker JC, Hauschild A, Romanini A, Danielli R, Dummer R, Trefzer U, Elia G, Neri D, Garbe C.

Cancer Immunol Immunother. 2019 Sep;68(9):1547-1559. doi: 10.1007/s00262-019-02383-z. Epub 2019 Sep 3.

PMID:
31482307
11.

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Schadendorf D.

Eur J Cancer. 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21.

PMID:
31445199
12.

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.

Eur J Cancer. 2019 Sep;119:97-106. doi: 10.1016/j.ejca.2019.07.016. Epub 2019 Aug 19.

13.

Binimetinib in heavily pretreated patients with NRAS-mutant melanoma with brain metastases.

Goldinger SM, Valeska Matter A, Urner-Bloch U, Narainsing J, Micaletto S, Blume I, Mangana J, Dummer R.

Br J Dermatol. 2019 Aug 22. doi: 10.1111/bjd.18449. [Epub ahead of print] No abstract available.

PMID:
31436845
14.

Erratum to "Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma".

Curioni-Fontecedro A, Pitocco R, Schoenewolf NL, Holzmann D, Soldini D, Dummer R, Calvieri S, Moch H, Fitsche A, Mihic-Probst D.

Biomed Res Int. 2019 Jul 22;2019:5256364. doi: 10.1155/2019/5256364. eCollection 2019.

15.

How I treat metastatic melanoma.

Dummer R, Mangana J, Frauchiger AL, Lang C, Micaletto S, Barysch MJ.

ESMO Open. 2019 Jul 21;4(Suppl 2):e000509. doi: 10.1136/esmoopen-2019-000509. eCollection 2019. Review.

16.

[Histiocytosis in the dermatological context of the new classification].

Lang C, Maul JT, Krähenbühl L, Dimitriou F, Dummer R.

Hautarzt. 2019 Sep;70(9):691-699. doi: 10.1007/s00105-019-4460-2. Review. German.

PMID:
31414152
17.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.

Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suciu S, Testori A.

Eur J Cancer. 2019 Sep;119:1-10. doi: 10.1016/j.ejca.2019.07.001. Epub 2019 Aug 7.

PMID:
31400634
18.

Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.

Ramelyte E, Dummer R, Guenova E.

Expert Opin Investig Drugs. 2019 Sep;28(9):799-809. doi: 10.1080/13543784.2019.1654995. Epub 2019 Aug 18. Review.

PMID:
31398295
19.

A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors.

Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flückiger-Mangual S, Vukolic A, Eichhoff O, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ.

Clin Cancer Res. 2019 Aug 2. doi: 10.1158/1078-0432.CCR-19-0253. [Epub ahead of print]

PMID:
31375515
20.

Is single versus combination therapy problematic in the treatment of cutaneous melanoma?

Krattinger R, Ramelyte E, Dornbierer J, Dummer R.

Expert Rev Clin Pharmacol. 2019 Jul 31. doi: 10.1080/17512433.2019.1650641. [Epub ahead of print]

PMID:
31364890

Supplemental Content

Loading ...
Support Center